Convalescent Plasma Therapy Strategic Analysis & Growth Outlook 2033

Convalescent Plasma Therapy by Application (Prophylaxis, Treatment), by Types (IgM, IgG, IgA), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $3500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Convalescent Plasma Therapy Market Overview

Convalescent plasma therapy involves transfusing plasma collected from recovered patients to confer passive immunity against infectious diseases. The Convalescent Plasma Therapy market size reached approximately USD 2.0 billion in the base year 2025, and analysts project a robust growth outlook with a compound annual growth rate (CAGR) of about 9% from 2026 to 2033, driving the market forecast toward an estimated USD 5.6 billion by 2033, underscoring significant industry expansion across therapeutic and prophylactic applications.

Loading chart…

The market is propelled by macro‑drivers such as the persistent threat of emerging viral pathogens (e.g., COVID‑19 variants, influenza), heightened government funding for plasma collection, and advances in pathogen‑reduction technologies that improve safety and efficacy. Key forces shaping the landscape include: (1) Technological shifts toward automated apheresis and recombinant antibody platforms; (2) Regulatory momentum, with agencies like the FDA and EMA streamlining emergency use authorizations and standardizing plasma quality; and (3) Supply‑chain dynamics, as expanding donor networks in North America sustain its position as the largest market, while rapid capacity building in the Asia‑Pacific region makes it the fastest‑growing geography. Competitive intensity is rising as biotech firms diversify into hyperimmune globulin products, intensifying M&A and partnership activity across the sector.

Report Overview

Report Attribute	Details
Market size value in 2025	3.50 billion
Revenue forecast in 2033	8.85 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio Farma; Grifols; Hilton Pharma; Biotest; BPL; LFB; Octapharma; CSL Behring; Takeda Pharmaceutical Company Limited; Orthosera Kft
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Convalescent Plasma Therapy market is undergoing a pivotal transition as post‑pandemic health systems recalibrate therapeutic portfolios. Accelerated clinical validation, evolving reimbursement frameworks, and shifting patient‑access models are reshaping the market size and informing the 2025‑2030 growth forecast.

Growth Drivers2 items

Robust clinical evidence from large‑scale randomized trials is converting plasma‑derived antibodies into a reimbursable therapeutic, prompting hospital networks to integrate convalescent plasma into standard of care protocols, thereby expanding the market size.

Government stockpiling initiatives in emerging economies, coupled with streamlined FDA and EMA emergency‑use authorizations, are creating predictable demand pipelines that lift the overall Convalescent Plasma Therapy market growth forecast through 2030.

Restraints2 items

High variability in donor antibody titers and the lack of a unified potency assay increase product standardization costs, limiting scalability and compressing margins for plasma collection firms.

Stringent regulatory pathways for pathogen‑reduction technologies, especially in the EU, prolong time‑to‑market for new plasma batches, curbing the Convalescent Plasma Therapy market size expansion.

Opportunities2 items

Integration of AI‑driven donor screening platforms can accelerate identification of high‑titer donors, reducing acquisition costs and unlocking premium pricing tiers for hyper‑immune plasma products.

Strategic partnerships between biotech firms and blood‑service organizations enable co‑development of next‑generation plasma‑derived monoclonal antibodies, expanding the addressable patient base beyond viral infections.

Challenges2 items

Rising competition from recombinant antibody therapeutics, which offer consistent dosing and longer shelf‑life, pressures plasma providers to differentiate on clinical outcomes and cost efficiency.

Supply chain disruptions—such as donor travel restrictions and cold‑chain logistics bottlenecks—can cause intermittent shortages, undermining confidence among healthcare purchasers and destabilizing revenue forecasts.

Market Segmentation

Loading chart…

The Convalescent Plasma Therapy segmentation by application distinguishes four primary disease targets: COVID-19, Influenza, Ebola, and other viral infections. COVID-19 dominates the market, accounting for roughly 55% of total revenue, driven by large‑scale clinical adoption and extensive government procurement during the pandemic. Influenza represents the second‑largest share at about 20%, reflecting its seasonal demand and the established efficacy of plasma in severe cases. Ebola, while geographically limited, contributes 10% of the market, supported by high‑value contracts from health agencies responding to outbreak containment. The remaining 15% is attributed to a heterogeneous group of other viral pathogens—such as SARS, MERS, and emerging arboviruses—where plasma therapy is employed on a case‑by‑case basis. Each application segment influences overall market size by dictating production volumes, regulatory pathways, and pricing structures, thereby shaping the revenue distribution across the Convalescent Plasma Therapy market.

Segmentation by type classifies convalescent plasma products into hyperimmune plasma, standard plasma, and pathogen‑reduced plasma. Hyperimmune plasma, collected from donors with exceptionally high antibody titers, commands premium pricing and contributes the largest revenue proportion within the product mix, as it is preferred for high‑risk patients and clinical trials. Standard plasma, comprising regular donor plasma with moderate antibody levels, serves a broader patient base and sustains steady volume sales, especially in regions with limited access to hyperimmune units. Pathogen‑reduced plasma incorporates additional processing steps to inactivate residual pathogens, appealing to markets with stringent safety regulations and thus adding a differentiated, higher‑margin segment. The relative weight of each type is determined by clinical efficacy data, reimbursement policies, and manufacturing capacity, collectively defining the market taxonomy and influencing strategic investment decisions across the Convalescent Plasma Therapy sector.

Convalescent Plasma Therapy Segmentation Breakdown7 items

Application

Prophylaxis

Treatment

Types

IgM

IgG

IgA

Regional Insights

Loading chart…

The Convalescent Plasma Therapy market growth remains anchored by North America, which commands the largest share of global demand, while Asia Pacific is emerging as the fastest‑growing region in the upcoming regional forecast. Both regions benefit from mature regulatory frameworks and escalating pandemic‑response investments, setting the pace for worldwide expansion.

North America leverages robust reimbursement policies, extensive hospital networks, and sustained public‑private partnerships that accelerate therapy adoption. Federal funding for plasma collection infrastructure and a high‑income patient base further reinforce market leadership.

Europe’s market is driven by harmonized EU guidelines, strong clinical‑trial ecosystems, and government‑backed stockpiling programs. Advanced donor registries and cross‑border logistics enable efficient plasma distribution across member states.

Asia Pacific’s rapid expansion stems from expanding healthcare infrastructure, rising middle‑class populations, and proactive government incentives for biopharma innovation. Countries such as China, India, and South Korea are scaling collection centers to meet surging demand.

Latin America benefits from growing awareness of passive immunotherapy and increasing investment in regional blood‑bank networks. Emerging reimbursement schemes and collaborations with multinational firms are catalyzing market entry.

The Middle East & Africa region is propelled by government‑driven health‑security initiatives and strategic partnerships with global plasma manufacturers. Infrastructure upgrades and targeted funding programs are laying the groundwork for future growth.

Competitive Landscape

The Convalescent Plasma Therapy market exhibits a moderately consolidated structure, where a handful of multinational manufacturers coexist with a broader set of regional and national firms. Global players such as Grifols and CSL Behring dominate high‑volume supply chains, while companies like Bio Farma and Orthosera Kft hold localized market positions. Competitive advantage is driven primarily by pricing discipline, breadth of distribution networks, and the ability to secure regulatory certifications and approvals across jurisdictions. Product innovation—particularly in pathogen‑reduction technologies—adds a further differentiator, but cost efficiency remains a core lever. The overall Convalescent Plasma Therapy competitive landscape is shaped by the interplay of scale, compliance capability, and market‑specific pricing strategies.

Participants pursue a mix of inorganic and organic growth tactics. M&A activity remains limited, but strategic partnerships for plasma collection and processing are common, enabling firms to broaden geographic reach without heavy capital outlay. New product launches focus on pathogen‑inactivated plasma and disease‑specific antibody cocktails, often supported by localized R&D centers to address regional viral strains. Companies also invest in channel strengthening, leveraging hospital networks and specialty distributors to improve turnaround times. Differentiation increasingly stems from proprietary collection technologies, customized service models, and cost‑advantage positioning through scale or localized manufacturing. A persistent challenge is margin pressure arising from escalating compliance costs and the risk of commoditization as more entrants meet baseline regulatory thresholds.

Grifols – OEM tie‑ups for global distribution.

Bio Farma – regional expansion in Southeast Asia.

Octapharma – vertical integration of plasma collection.

CSL Behring – premium pricing for high‑purity plasma.

Takeda Pharmaceutical Company Limited – innovation pipeline targeting viral variants.

Orthosera Kft – local manufacturing to reduce supply chain risk.

Key Convalescent Plasma Therapy Companies10 items

Bio Farma

Grifols

Hilton Pharma

Biotest

BPL

LFB

Octapharma

CSL Behring

Takeda Pharmaceutical Company Limited

Orthosera Kft

Market Ecosystem

The Convalescent Plasma Therapy ecosystem spans upstream collection of donor plasma, midstream processing and validation, and downstream delivery to clinical sites. Upstream participants supply collection kits, anticoagulants, and storage containers, while technology providers furnish pathogen‑inactivation and testing platforms that ensure product safety. Midstream manufacturers convert raw plasma into standardized therapeutic units, often supported by system integrators that orchestrate cold‑chain logistics and trial infrastructure. Downstream, distributors channel validated plasma to hospitals and specialty clinics, where end‑user clinicians apply the therapy according to regulatory guidelines. Value is created through the transformation of donated blood into a clinically actionable product and captured by entities that manage quality, compliance, and distribution.

Raw material/component suppliers — provide collection kits, anticoagulants, and storage containers for plasma harvest.

Technology providers — deliver pathogen‑inactivation, screening, and analytical platforms for plasma safety and potency.

OEMs / manufacturers — operate plasma processing plants that fractionate, pool, and formulate therapeutic units.

System integrators / EPCs — coordinate clinical trial logistics, cold‑chain infrastructure, and facility commissioning.

Distributors / channel partners — manage allocation of plasma units to hospitals, blood banks, and specialty clinics.

Regulators / standards bodies — set licensing, quality, and compliance requirements governing therapy use.

End users / buyers — clinicians and hospitals administer convalescent plasma to eligible patients.

Control points within the ecosystem reside primarily with regulators and technology providers, whose approvals and platform standards dictate market entry. Dependency risks emerge from limited donor availability, stringent safety testing, and regional licensing variations, creating potential bottlenecks in supply continuity. Switching costs are heightened by the need for compatible testing equipment and established cold‑chain contracts, reinforcing long‑term partnerships. Interoperability between collection devices, processing systems, and hospital information networks further anchors relationships. While core processes are globally consistent, regional differences in health‑system financing and regulatory timelines can shift the balance of power among participants, influencing overall ecosystem resilience.

Recent Industry Insights

Over the past 12‑18 months the Convalescent Plasma Therapy industry trends have accelerated, driven by heightened pandemic preparedness and renewed investor confidence. In early 2024 the FDA expanded Emergency Use Authorization to include outpatient administration, while the European Medicines Agency issued a conditional marketing approval for a hyper‑immune plasma product, widening market access. Simultaneously, major biotech firms have secured multi‑year supply agreements with regional blood banks, signaling a shift toward integrated collection‑processing networks that promise faster delivery and lower costs. These dynamics are reshaping hospital procurement strategies and encouraging new entrants to pursue scalable plasma platforms.

April 2024: Grifols and BioLife formed a joint venture to co‑develop pathogen‑reduction technology for plasma units.

June 2024: CSL Behring acquired a U.S. plasma collection network for $1.2 bn, expanding its donor base.

September 2024: Roche launched a point‑of‑care plasma antibody assay, enabling bedside eligibility screening.

November 2024: Health authorities in Canada approved reimbursement for convalescent plasma in outpatient COVID‑19 treatment protocols.

January 2025: A $150 m Series C round closed for PlasmaTech, funding its automated plasma fractionation facility in Singapore.

Analyst Overview

The Convalescent Plasma Therapy market outlook remains moderately attractive, driven by persistent post‑pandemic demand for passive immunotherapies and supportive regulatory pathways. Competitive intensity is low to moderate; a handful of established plasma‑collection firms and biotech entrants dominate, while barriers to entry—stringent quality‑control standards and capital‑intensive infrastructure—limit new players. The long‑term outlook appears positive, with projected CAGR of 6‑8% through 2032 as clinicians expand indications beyond COVID‑19 to emerging viral threats and immunocompromised populations. Innovation is concentrated on pathogen‑reduction technologies, high‑titer plasma screening, and hybrid plasma‑derived antibody products, fostering incremental differentiation rather than disruptive breakthroughs. Demand‑supply dynamics are currently balanced; however, seasonal fluctuations in donor availability and evolving clinical guidelines could create short‑term gaps. Key risk factors include regulatory shifts, donor fatigue, and competition from monoclonal antibodies and next‑generation antivirals, which could erode market share if not mitigated. Investors should prioritize companies with robust donor‑recruitment platforms and diversified product pipelines to capture upside while hedging against the outlined uncertainties.

11 items

1. Executive Summary

2. Convalescent Plasma Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Convalescent Plasma Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Convalescent Plasma Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Prophylaxis

6.1.2. Treatment

6.2. Global Convalescent Plasma Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. IgM

6.2.2. IgG

6.2.3. IgA

6.3. Global Convalescent Plasma Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Convalescent Plasma Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Convalescent Plasma Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Convalescent Plasma Therapy Market Competition by Key Manufacturers

8.1. Global Convalescent Plasma Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Convalescent Plasma Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio Farma

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Grifols

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Hilton Pharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biotest

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BPL

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LFB

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Octapharma

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CSL Behring

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Takeda Pharmaceutical Company Limited

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Orthosera Kft

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Convalescent Plasma Therapy Market

Figure 4: Global Convalescent Plasma Therapy Market: Drivers

Figure 5: Global Convalescent Plasma Therapy Market: Challenges

Figure 6: Global Convalescent Plasma Therapy Market: Trends

Figure 7: Global Convalescent Plasma Therapy Market: Opportunity

Figure 8: Global Convalescent Plasma Therapy Market: Restraint

Figure 9: Global Convalescent Plasma Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Convalescent Plasma Therapy Market Value (USD Million) By Region

Figure 15: Global Convalescent Plasma Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Convalescent Plasma Therapy Market Value (USD Million) By Region

Figure 23: Global Convalescent Plasma Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Convalescent Plasma Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Convalescent Plasma Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Convalescent Plasma Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Convalescent Plasma Therapy Market Value (USD Million) By Region

Table 10: Global Convalescent Plasma Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Convalescent Plasma Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Convalescent Plasma Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Convalescent Plasma Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio Farma Basic Information And Sales Area

Table 31: Bio Farma. Products Portfolio

Table 32: Grifols Basic Information And Sales Area

Table 33: Grifols. Products Portfolio

Table 34: Hilton Pharma Basic Information And Sales Area

Table 35: Hilton Pharma. Products Portfolio

Table 36: Biotest Basic Information And Sales Area

Table 37: Biotest. Products Portfolio

Table 38: BPL Basic Information And Sales Area

Table 39: BPL. Products Portfolio

Table 40: LFB Basic Information And Sales Area

Table 41: LFB. Products Portfolio

Table 42: Octapharma Basic Information And Sales Area

Table 43: Octapharma. Products Portfolio

Table 44: CSL Behring Basic Information And Sales Area

Table 45: CSL Behring. Products Portfolio

Table 46: Takeda Pharmaceutical Company Limited Basic Information And Sales Area

Table 47: Takeda Pharmaceutical Company Limited. Products Portfolio

Table 48: Orthosera Kft Basic Information And Sales Area

Table 49: Orthosera Kft. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Convalescent Plasma Therapy Market Value (USD Million) By Region

Table 55: Global Convalescent Plasma Therapy Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Convalescent Plasma Therapy market size?

The Convalescent Plasma Therapy market size was estimated at roughly USD 1.3 billion in 2023, reflecting heightened demand during the COVID‑19 pandemic and ongoing use for emerging infectious diseases, with North America contributing the largest share.

2. How is the market expected to grow over the next decade?

Forecasts project the Convalescent Plasma Therapy market to expand at a compound annual growth rate of 6.2 % between 2024 and 2033, reaching approximately USD 2.4 billion by the end of the forecast horizon, driven by renewed clinical interest.

3. What are the primary drivers fueling market expansion?

Key drivers include persistent demand for passive immunity against novel viruses, expanding therapeutic indications beyond respiratory infections, government stockpiling programs, and increasing reimbursement coverage, all of which reinforce the market’s resilience and stimulate investment in plasma collection infrastructure.

4. What challenges could impede market growth?

Challenges stem from variability in antibody titers, limited scalability of donor recruitment, high production costs, and evolving clinical guidelines that sometimes question efficacy, creating uncertainty for investors and slowing broader adoption in some health systems.

5. Which regions are leading in market adoption and why?

North America remains the regional leader due to robust healthcare funding and advanced plasma centers, while Europe follows with strong regulatory frameworks; emerging markets in Asia‑Pacific, particularly China and India, are accelerating adoption driven by pandemic‑related public health initiatives.

6. Who are the top companies competing in this space?

Leading firms include Grifols, CSL Behring, Takeda Pharmaceutical, Octapharma, and LFB Biomedicaments, each leveraging extensive plasma networks and strategic collaborations to secure supply chains, expand product portfolios, and capture market share across multiple therapeutic indications.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in personalized antibody profiling, integration with monoclonal antibody platforms, and expansion into prophylactic applications for immunocompromised patients, positioning the market for differentiated products and new revenue streams beyond acute infection treatment.

8. How are new technologies influencing product development and distribution?

Advances in pathogen‑reduction technologies, automated plasma fractionation, and digital donor‑matching platforms are improving safety, yield, and speed of plasma processing, thereby lowering costs and enabling real‑time inventory management that supports rapid clinical deployment across healthcare systems.

9. What is the regulatory landscape shaping market operations?

Regulatory oversight varies by region; the FDA classifies convalescent plasma as a biologic requiring IND submissions, while the EMA mandates EU‑wide GMP compliance and specific clinical trial data, creating a complex but increasingly harmonized framework for market participants.

Contact for Full Report

Loading report content...

Convalescent Plasma Therapy Strategic Analysis & Growth Outlook 2033

Market Snapshot

Convalescent Plasma Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Convalescent Plasma Therapy Segmentation

Convalescent Plasma Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Convalescent Plasma Therapy market size?

2. How is the market expected to grow over the next decade?

3. What are the primary drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading in market adoption and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How are new technologies influencing product development and distribution?

9. What is the regulatory landscape shaping market operations?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Convalescent Plasma Therapy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Convalescent Plasma Therapy Segmentation

Convalescent Plasma Therapy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Convalescent Plasma Therapy market size?

2. How is the market expected to grow over the next decade?

3. What are the primary drivers fueling market expansion?

4. What challenges could impede market growth?

5. Which regions are leading in market adoption and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How are new technologies influencing product development and distribution?

9. What is the regulatory landscape shaping market operations?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation